Related Experiment Video
Updated: Sep 30, 2025
10:01
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
11.0K
A Case-Control Study of the Dose-Response Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Acute
Mengnan Zhao1,2, Dan Zhao1, Yuning Li1
1Department of Clinical Epidemiology and Evidence-Based Medicine, The First Affiliated Hospital, China Medical University, Shenyang, China.
Frontiers in Cardiovascular Medicine
|March 17, 2022
Summary
Elevated thrombin activatable fibrinolysis inhibitor (TAFI) levels are linked to a higher risk of acute myocardial infarction (AMI). TAFI is an independent risk factor for AMI, suggesting its potential role in risk stratification.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Research
Background:
- Acute myocardial infarction (AMI) is a critical manifestation of acute coronary syndrome (ACS).
- Prolonged myocardial ischemia leading to cell death poses a significant risk of sudden death.
- Understanding factors contributing to AMI is crucial for prevention and management.
Purpose of the Study:
- To investigate the association between thrombin activatable fibrinolysis inhibitor (TAFI) and AMI.
- To provide evidence for TAFI's role in AMI pathogenesis.
- To explore TAFI's potential in AMI prevention strategies.
Main Methods:
- Retrospective study including 78 AMI patients and 150 controls.
- Serum TAFI concentration measured using immune turbidimetry.
- Logistic regression and restricted cubic spline analysis used to assess TAFI's relationship with AMI risk.
Main Results:
- Serum TAFI levels were significantly higher in AMI patients compared to controls (P = 0.003).
- High TAFI levels increased AMI risk by 2.24 times (P = 0.007), and 2.74 times after adjusting for risk factors (P = 0.025).
- A significant dose-response relationship observed between increasing serum TAFI concentration and AMI risk (P = 0.0387).
Conclusions:
- Higher serum TAFI levels are associated with AMI.
- TAFI is identified as an independent risk factor for AMI.
- Serum TAFI levels show a dose-dependent effect on AMI risk, indicating its utility in risk stratification.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
959
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
959
01:29Venous Thrombosis III: Interprofessional Care
41
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
41
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Acute Coronary Syndrome III: Diagnostic Studies
35
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
35
01:16Clot Retraction and Fibrinolysis
7.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.1K
01:28Acute Coronary Syndrome IV: Interprofessional Care
42
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
42